Karyopharm Therapeutics Inc. | Mutual Funds
Mutual Funds that own Karyopharm Therapeutics Inc.
SPDR S&P Biotech ETF
1,506,604
2.49%
3,876
0.54%
09/06/2018
Vanguard Total Stock Market Index Fund
1,386,857
2.29%
0
0%
07/31/2018
Fidelity Select Biotechnology Portfolio
1,175,343
1.94%
0
0.27%
07/31/2018
iShares Russell 2000 ETF
1,014,507
1.68%
-543
0.04%
09/06/2018
Franklin Small Cap Growth Fund
767,086
1.27%
-510,600
0.54%
03/31/2018
Wellington Mgmt. Port (Dublin) Plc - Global Health Care Eq.
767,053
1.27%
96,053
0.75%
12/31/2017
FTIF SICAV - Franklin Biotechnology Discovery Fund
763,995
1.26%
53,200
0.69%
06/30/2018
iShares Nasdaq Biotechnology ETF
696,385
1.14%
-9,114
0.15%
09/06/2018
Candriam Equities L - Biotechnology
694,500
1.14%
289,500
1.08%
07/31/2018
Vanguard Extended Market Index Fund
658,370
1.09%
5,500
0.02%
07/31/2018
| Address |
85 Wells Avenue
Newton Massachusetts 02459
United States
|
|
Employees
|
- |
| Website |
http://www.karyopharm.com |
| Updated |
07/08/2019 |
| Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, The engages in the discovery, development, and commercialization of drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A. |
